Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma

被引：0
|
作者：
Thompson, MA
Pro, B
Sarris, A
Hagemeister, FB
Goy, A
Bleyer, A
Cabanillas, FF
Samaniego, F
Fayad, LE
机构：
[1] MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[2] Hygeia Hosp, Athens, Greece
[3] Harvard Med Int, Athens, Greece
[4] Hackensack Univ, Med Ctr, Div Lymphoma, Ctr Canc, Hackensack, NJ USA
[5] Auxilio Mutuo Hosp, Ctr Canc, San Juan, PR 00919 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2681
引用
收藏
页码：753A / 753A
页数：1
相关论文
共 50 条
  • [1] Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901
    Czuczman, Myron S.
    Porcu, Pierluigi
    Johnson, Jeffrey
    Niedzwiecki, Donna
    Kelly, Michael
    Hsi, Eric D.
    Cook, James R.
    Canellos, George
    Cheson, Bruce D.
    LEUKEMIA & LYMPHOMA, 2007, 48 (01) : 97 - 103
  • [2] Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy
    Goy, A
    Bleyer, A
    Hagemeister, F
    Fayad, L
    Pro, B
    Romaguera, J
    Samaniego, F
    Sarris, AH
    Hart, S
    Cabanillas, F
    Murgo, A
    Duvic, M
    Rodriguez, MA
    BLOOD, 2003, 102 (11) : 639A - 639A
  • [3] Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group
    Berg, SL
    Blaney, SM
    Devidas, M
    Lampkin, TA
    Murgo, A
    Bernstein, M
    Billett, A
    Kurtzberg, J
    Reaman, G
    Gaynon, P
    Whitlock, J
    Krailo, M
    Harris, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3376 - 3382
  • [4] Activity of compound 506U78 in patients with refractory T-cell malignancies: A POG/CCG intergroup phase 2 study.
    Berg, SL
    Blaney, SM
    Bernstein, M
    Kurtzberg, J
    Devidas, M
    Lampkin, T
    Murgo, AJ
    Harris, MB
    BLOOD, 2003, 102 (11) : 226A - 226A
  • [5] Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma: Updated Results
    Holkova, Beata
    Kmieciak, Maciej
    Bose, Prithviraj
    Ma, Shuo
    Kimball, Amy
    Tombes, Mary Beth
    Shrader, Ellen
    Wan, Wen
    Weir-Wiggins, Caryn
    Stoddert, Elizabeth
    Singh, Amanda Garnett
    Dean, April
    Conine, Sarah
    Sankala, Heidi
    Roberts, John D.
    Shea, Thomas C.
    Grant, Steven
    BLOOD, 2014, 124 (21)
  • [6] Phase II study of compound GW506U78 (AraG) in patients with T-cell and B-cell non Hodgkin lymphomas (NHL).
    Goy, A
    Sarris, AH
    Bleyer, A
    Duvic, M
    Mesina, O
    Dang, NH
    Fayad, L
    Hagemeister, F
    McLaughlin, P
    Pro, B
    Rodriguez, MA
    Romaguera, J
    Samagieno, F
    Younes, A
    BLOOD, 2002, 100 (11) : 304B - 304B
  • [7] CALGB 59901: Results of a phase II study of 506U78 in CTCL and PTCL.
    Czuczman, MS
    Porcu, P
    Johnson, J
    Niedzwiecki, D
    Canellos, GP
    Cheson, BD
    BLOOD, 2004, 104 (11) : 682A - 682A
  • [8] A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma
    Holkova, Beata
    Yazbeck, Victor
    Kmieciak, Maciej
    Bose, Prithviraj
    Ma, Shuo
    Kimball, Amy
    Tombes, Mary Beth
    Shrader, Ellen
    Wan, Wen
    Weir-Wiggins, Caryn
    Singh, Amanda
    Hogan, Kevin T.
    Conine, Sarah
    Sankala, Heidi
    Roberts, John D.
    Shea, Thomas C.
    Grant, Steven
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1349 - 1357
  • [9] Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma
    Holkova, Beata
    Shea, Thomas C.
    Bose, Prithviraj
    Tombes, Mary Beth
    Shrader, Ellen
    Wan, Wen
    Weir-Wiggins, Caryn
    Stoddert, Elizabeth
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Grant, Steven
    BLOOD, 2012, 120 (21)
  • [10] A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Bennani, N. Nora
    Pederson, Levi D.
    Atherton, Pamela
    Micallef, Ivana
    Colgan, Joseph P.
    Thanarajasingam, Gita
    Nowakowski, Grzegorz
    Witzig, Thomas E.
    Feldman, Andrew L.
    Ansell, Stephen M.
    BLOOD, 2019, 134
12345